OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc. Show more

Location: 777 Township Line Road, Yardley, PA, 19067, United States | Website: https://www.optinose.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare

Market Cap

97.22M

52 Wk Range

$4.82 - $20.02

Previous Close

$9.60

Open

$9.60

Volume

N/A

Day Range

$9.60 - $9.60

Enterprise Value

153.9M

Cash

72.93M

Avg Qtr Burn

-8.552M

Insider Ownership

6.34%

Institutional Own.

72.37%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XHANCE (fluticasone propionate) Details Nasal polyps, Chronic sinusitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XHANCE (fluticasone propionate) Details Chronic sinusitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.